CMMB - Chemomab Highlights New Data Supporting Lead Drug Candidate for Rare Liver Disease

Chemomab Therapeutics (NASDAQ: CMMB ) unveiled new clinical results that they will present at the EASL 2025 Annual Congress on May 7-10 , providing additional support for its lead drug candidate, nebokitug (CM-101), as a potential treatment for primary sclerosing cholangitis (PSC) and related inflammatory diseases.

In its Phase 2 SPRING trial, Chemomab studied how nebokitug impacted biological markers tied to disease progression. According to the data, patients treated with the drug showed meaningful improvements in markers related to inflammation and fibrosis -- two major drivers of PSC. These improvements were dose-dependent, meaning greater exposure to nebokitug was linked with better results.

Chemomab also reported that patients receiving the drug experienced improvements in important liver function indicators, with reductions in liver enzyme levels and improved scores on liver stiffness measurements -- a key sign of disease severity.

Nebokitug is designed to block a specific protein, CCL24, that plays a role in inflammation and tissue scarring. The drug has already received Orphan Drug and Fast Track designations from the FDA for PSC, signaling its potential to address a significant unmet medical need.

Chief Executive Officer Adi Mor stated that the latest results strengthen the company's belief that nebokitug could become the first approved treatment for PSC, a rare and progressive liver disease with limited options for patients today. Chemomab is preparing for discussions with regulators regarding a possible Phase 3 trial that would focus on confirming clinical benefits.